Fol. Biol. 2019, 65, 43-52
https://doi.org/10.14712/fb2019065010043
Trichostatin A Inhibits Rhabdomyosarcoma Proliferation and Induces Differentiation through MyomiR Reactivation
References
1. , S. R., Humphreys, K. J., McKinnon, R. A., Michael, M. Z. (2015) Impact of histone deacetylase inhibitors on microRNA expression and cancer therapy: a review. Drug Dev. Res. 76, 296-317.
<https://doi.org/10.1002/ddr.21268>
2. , M., Weber, K., Droste, R., Osborn, M. (1985) Desmin is a specific marker for rhabdomyosarcomas of human and rat origin. Am. J. Pathol. 118, 85-95.
3. , J., Gordon, A., McManus, A., Shipley J., Pritchard- Jones, K. (1999) Disruption of imprinted genes at chromosome region 11p15.5 in paediatric rhabdomyosarcoma. Neoplasia 4, 340-348.
<https://doi.org/10.1038/sj.neo.7900052>
4. , M. I., Patel, M., Singh, B., Jameson, J. S., Pringle, J. H. (2012) MicroRNA manipulation in colorectal cancer cells: from laboratory to clinical application. J. Transl. Med. 10, 128.
<https://doi.org/10.1186/1479-5876-10-128>
5. , D., Martone, J., Girardi, E., Cesana, M., Incitti, T., Morlando, M., Nicoletti, C., Santini, T., Sthandier, O., Barberi, L., Auricchio, A., Musarò, A., Bozzoni, I. (2010) MicroRNAs involved in molecular circuitries relevant for the Duchenne muscular dystrophy pathogenesis are controlled by the dystrophin/nNOS pathway. Cell Metab. 12, 341-351.
<https://doi.org/10.1016/j.cmet.2010.07.008>
6. , S., Pedone, P. V., Cavazzana, A. O., Basso, G., Luksch, R., d’Amore, E. S., Carli, M,, Bruni, C. B., Riccio, A. (1997) Expression and parental imprinting of the H19 gene in human rhabdomyosarcoma. Oncogene 14, 1503-1510.
<https://doi.org/10.1038/sj.onc.1200956>
7. , H., Jeung, H. C., Jung, J. J., Kim, T. S., Rha, S. Y., Chung, H. C. (2011) Identification of genes associated with chemo-sensitivity to SAHA/taxane combination treatment in taxane-resistant breast cancer cells. Breast Cancer Res. Treat. 125, 55-63.
<https://doi.org/10.1007/s10549-010-0825-z>
8. , A., Cross, N. C. P. (2011) Aberrations of EZH2 in cancer. Clin. Cancer Res. 17, 2613-2618.
<https://doi.org/10.1158/1078-0432.CCR-10-2156>
9. , B., Dias, P., Jenkins, J. J., Savell, V., Parham, D. M. (1998) Methylation alterations of the MyoD1 upstream region predict rhabdomyosarcoma histology. Modern Pathol. 11, 1071-1079.
10. , C., Fritz, V., Henriquet, C., Apparailly, F., Fernandez, P. L., Iborra, F., Avances, C., Villalba, M., Culine, S., Fajas, L. (2009) miR-143 interferes with ERK5 signaling, and abrogates prostate cancer progression in mice. PLoS One 4, e7542.
<https://doi.org/10.1371/journal.pone.0007542>
11. , M. H., Zhao H., Womer, R. B., Barr, F. G. (2001) Proliferative and apoptotic differences between alveolar rhabdomyosarcoma subtypes: a comparative study of tumors containing PAX3-FKHR or PAX7-FKHR gene fusions. Med. Pediatr. Oncol. 37, 83-89.
<https://doi.org/10.1002/mpo.1174>
12. , C. G., Montarras, D., Pallafacchina, G., Rocancourt, D., Cumano, A., Conway, S. J., Buckingham, M. (2009) Muscle stem cell behavior is modified by microRNA-27 regulation of Pax3 expression. Proc. Natl. Acad. Sci. USA 106, 13383-13387.
<https://doi.org/10.1073/pnas.0900210106>
13. , C., Landuzzi, L., Nicoletti, G., Lollini, P. L., Nanni, P. (2009) Molecular and cellular biology of rhabdomyosarcoma. Future Oncol. 5, 1449-1475.
<https://doi.org/10.2217/fon.09.97>
14. , L., Ni, J., Yang, F., Huang, L., Deng, H., Wu, Y., Ding, X., Tang, J. (2017) Promising therapeutic role of miR-27b in tumor. Tumour Biol. 39, 1010428317691657.
15. , T., Bonvini, P., Sartori, F., Marrone, A., Iolascon, A., Rosolen, A. (2006) Plakoglobin is differentially expressed in alveolar and embryonal rhabdomyosarcoma and is regulated by DNA methylation and histone acetylation. Carcinogenesis 27, 1758-1767.
<https://doi.org/10.1093/carcin/bgl008>
16. , M., Meller, I., Orr-Urtreger, A. (2007) FGFR1 over-expression in primary rhabdomyosarcoma tumors is associated with hypomethylation of a 5′ CpG island and abnormal expression of the AKT1, NOG, and BMP4 genes. Genes Chromosomes Cancer 46, 1028-1038.
<https://doi.org/10.1002/gcc.20489>
17. , M., Montgomery, R. L., Olson, E. N. (2009) The many roles of histone deacetylases in development and physiology: implications for disease and therapy. Nat. Rev. Genet. 10, 32-42.
<https://doi.org/10.1038/nrg2485>
18. , M., Soleimani, M., Arefian, E., Sarookhani, M. M. (2015) Expression change of miR-214 and miR-133 during muscle differentiation. Cell J. 3, 461-470.
19. , H. (2016) Current status of treatment for pediatric rhabdomyosarcoma in the USA and Japan. Pediatr. Int. 58, 81-87.
<https://doi.org/10.1111/ped.12867>
20. , L., Xu, J., Jiao, Y., Li, H., Pan, Z., Duan, J., Gu, T., Hu, C., Wang, C. (2018) MiR-27b promotes muscle development by inhibiting MDFI expression. Cell Physiol. Biochem. 46, 2271-2283.
<https://doi.org/10.1159/000489595>
21. , M., Kakinuma, H., Kumazawa, T., Inoue T., Narita, S., Saito, M., Yuasa, T., Tsuchiya, N., Habuchi, T. (2007) Low concentrations of the histone deacetylase inhibitor, depsipeptide, enhance the effects of gemcitabine and docetaxel in hormone refractory prostate cancer cells. Oncol. Rep. 17, 761-767.
22. , P., Zikova, M., Bartunek, P., Sterba, J., Strnad, H., Kren, L., Sedlacek, R. (2015) The expression of c-Myb correlates with the levels of rhabdomyosarcoma-specific marker myogenin. Sci. Rep. 15, 1590.
23. , Z., Yu, X., Shen, J., Liu, Y., Chan, M. T., Wu, W. K. (2015) MicroRNA dysregulation in rhabdomyosarcoma: a new player enters the game. Cell Prolif. 48, 511-516.
<https://doi.org/10.1111/cpr.12199>
24. , S. E., Yao, Z., Keyes, C. C., Tapscott, S. J., Diede, S. J. (2012) Genome-wide DNA methylation studies suggest distinct DNA methylation patterns in pediatric embryonal and alveolar rhabdomyosarcomas. Epigenetics 7, 400-408.
<https://doi.org/10.4161/epi.19463>
25. , I., Giordano, A., Bagella, L. (2014) Roles of enhancer of zeste homolog 2: from skeletal muscle differentiation to rhabdomyosarcoma carcinogenesis. Cell Cycle 13, 516-527.
<https://doi.org/10.4161/cc.27921>
26. , J. J. (2008) MicroRNA-206: the skeletal musclespecific myomiR. Biochim. Biophys. Acta 1779, 682-691.
<https://doi.org/10.1016/j.bbagrm.2008.03.001>
27. , J. J., Esser, K. A., Peterson, C. A., Dupont-Versteegden, E. E. (2009) Evidence of MyomiR network regulation of β-myosin heavy chain gene expression during skeletal muscle atrophy. Physiol. Genomics 39, 219-226.
<https://doi.org/10.1152/physiolgenomics.00042.2009>
28. , S., Linabery, A. M., Charbonneau, B., Ross, J. A. (2009) Trends in childhood rhabdomyosarcoma incidence and survival in the United States, 1975-2005. Cancer 115, 4218-4226.
<https://doi.org/10.1002/cncr.24465>
29. , A. S. (1995) Rhabdomyosarcoma and other soft tissue sarcomas of childhood. Curr. Opin. Oncol. 7, 361-366.
<https://doi.org/10.1097/00001622-199507000-00012>
30. , D. M. (2001) Pathologic classification of rhabdomyosarcomas and correlations with molecular studies. Mod. Pathol. 14, 506-514.
<https://doi.org/10.1038/modpathol.3880339>
31. , W., Bishton, M., Johnstone, R. W., Prince, H. M. (2008) Histone deacetylase inhibitors in lymphoma and solid malignancies. Expert Rev. Anticancer Ther. 8, 413-432.
<https://doi.org/10.1586/14737140.8.3.413>
32. , R., Ciarapica, R., Giordano, A., Miele, L., Locatelli F. (2011) MicroRNAs in rhabdomyosarcoma: pathogenetic implications and translational potentiality. Mol. Cancer 10, 120.
<https://doi.org/10.1186/1476-4598-10-120>
33. , V., Consalvi, S., Giordani, L., Mozzetta, C., Barozzi, I., Sandoná, M., Ryan, T., Rojas-Muñoz, A., Madaro, L., Fasanaro, P. Borsellino, G., De Bardi, M., Frigè, G., Termanini, A., Sun, X., Rossant, J., Bruneau, B. G., Mercola, M., Minucci, S., Puri, P. L. (2014) HDAC-regulated myomiRs control BAF60 variant exchange and direct the functional phenotype of fibro-adipogenic progenitors in dystophic muscles. Genes Dev. 28, 841-857.
<https://doi.org/10.1101/gad.234468.113>
34. , G., Bowser, M. J., Shin, D. M., Barr, F. G., Ratajczak, M. Z. (2014) The paternally imprinted DLK1-GTL 2 locus is differentially methylated in embryonal and alveolar rhabdomyosarcomas. Int. J. Oncol. 44, 295-300.
<https://doi.org/10.3892/ijo.2013.2153>
35. , N. J., Malone, M. (2003) Myogenin and MyoD1 expression in paediatric rhabdomyosarcomas. J. Clin. Pathol. 56, 412-416.
<https://doi.org/10.1136/jcp.56.6.412>
36. , J. F., Yohe, M. E., Khan, J. (2015) Pediatric rhabdomyosarcoma. Crit. Rev. Oncog. 20, 227-243.
<https://doi.org/10.1615/CritRevOncog.2015013800>
37. , M. C., Brun, C. E., Rudnicki, M. A. (2016) Concise review: epigenetic regulation of myogenesis in health and disease. Stem Cells Transl. Med. 5, 282-290.
<https://doi.org/10.5966/sctm.2015-0266>
38. , M., Tkacz, M., Czerewaty, M., Poniewierska-Baran, A., Grymuła, K., Ratajczak, M. Z. (2015) 5‑Azacytidine inhibits human rhabdomyosarcoma cell growth by downregulating insulin‑like growth factor 2 expression and reactivating the H19 gene product miR‑675, which negatively affects insulin‑like growth factors and insulin signaling. Int. J. Oncol. 46, 2241-2250.
<https://doi.org/10.3892/ijo.2015.2906>
39. , P. N., Scrable, H., Shimada, H., Cavenee, W. K. (1991) Muscle-specific gene expression in rhabdomyosarcomas and stages of human fetal skeletal muscle development. Cancer Res. 51, 5100-5106.
40. , T., Phelps, M., Bammler, T. K., Mac- Donald, J. W., Jenkins, I., Chen, E. Y. (2015) Histone deacetylase inhibitors antagonize distinct pathways to suppress tumorigenesis of embryonal rhabdomyosarcoma. PLoS One 10, e0144320.
<https://doi.org/10.1371/journal.pone.0144320>
41. , F., Shehzada, A., Khanb, T., Kima, Y. Y. (2010) MicroRNAs: synthesis, mechanism, function, and recent clinical trials. Biochim. Biophys. Acta 11, 1231-1243.
<https://doi.org/10.1016/j.bbamcr.2010.06.013>
42. , C. (2012) Childhood rhabdomyosarcoma: recent advances and prospective views. J. Dent. Res. 91, 341-350.
<https://doi.org/10.1177/0022034511421490>
43. , J., Song, Y., Zhang, Y., Xiao, H., Sun, Q., Hou, N., Guo, S., Wang, Y., Fan, K., Zhan, D., Zha, L., Cao, Y., Li, Z., Cheng, X., Zhang, Y., Yang, X. (2012) Cardiomyocyte overexpression of miR-27b induces cardiac hypertrophy and dysfunction in mice. Cell Res. 22, 516-527.
<https://doi.org/10.1038/cr.2011.132>
44. , J., Hu, C. P., Gu, Q. H., Li, Y. P., Song, M. (2010) Trichostatin A sensitizes cisplatin-resistant A549 cells to apoptosis by up-regulating death-associated protein kinase. Acta Pharmacol. Sin. 31, 93-101.
<https://doi.org/10.1038/aps.2009.183>
45. , S., Shapiro, D. N., Helman, L. J. (1994) Activation of an imprinted allele of the insulin-like growth factor II gene implicated in rhabdomyosarcoma. J. Clin. Invest. 94, 445-448.
<https://doi.org/10.1172/JCI117344>
46. , X., Yashiro, M., Ren, J., Hirakawa, K. (2006) Histone deacetylase inhibitor, trichostatin A, increases the chemosensitivity of anticancer drugs in gastric cancer cell lines. Oncol. Rep. 16, 563-568.
47. , X., Jiang, S. J., Shang, B., Jiang, H. J. (2015) Effects of histone deacetylase inhibitor trichostatin A combined with cisplatin on apoptosis of A549 cell line. Thorac. Cancer 6, 202-208.
<https://doi.org/10.1111/1759-7714.12167>
